Resources

Under normal circumstances, blood glucose levels vary throughout the day. While it may not be of much significance to a healthy subject, the degree of these changes is of great importance to individuals with diabetes.

Patient, female, 54 years of age, type 2 diabetes and obesity, told me she thought her weight and subsequent type 2 diabetes related to overeating, especially large portions. She is being seen by a behavior therapist for her eating disorder. I started her on a GLP-1. Even at starting dose, she reported feeling more satiated, but still overeating. The dose was increased...

Dr. Christophe Arbet-Engels talks about how the empagliflozin study results were very positive in terms of lowering A1c, and goes over the basics of how the new class of SGLT-2 inhibitor drugs work, removing excess glucose, inducing some weight loss, and that there is potential for a decrease in blood pressure …

Christophe Arbet-Engels, MD, PhD, MBA, vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc., gives us a brief introduction to himself. Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. See more SGLT-2 Resources

Dr. Christophe Arbet-Engels, discusses some of the study results on empagliflozin in which more than 14,000 patients were involved in several different study configurations including monotherapy, empagliflozin as an add-on, and patients with renal impairment.   Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer …

Dr. Christophe Arbet-Engels explains how empagliflozin is being submitted to the FDA for treatment of diabetes indications and that there are different subgroups under this category. The FDA reviews the data and then may or may not grant approval or ask for more data. Christophe Arbet-Engels, MD, PhD, MBA, is vice …

Dr. Christophe Arbet-Engels discusses the clinical results of the empagliflozin studies focusing on the A1c drops which varied by study and were anywhere from .7 to 1% depending on the patient. He also differentiates between A1c drops due to weight loss and those due to the excretion of excess glucose which …

Dr. Christophe Arbet-Engels explains how empagliflozin could be dosed once approved. and that the highest dose showed the most benefit in trials with reductions in weight and blood pressure. Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. See more SGLT-2 Resources

Dr. Christophe Arbet-Engels continues his discussion of the potential for combining the SGLT-2 inhibitor empagliflozin with other drugs down the road, and that they will certainly be exploring these otpions.  Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. See more SGLT-2 Resources

Dr. Christophe Arbet-Engels explains that Boehringer Ingelheim will also be submitting empagliflozin internationally, and certainly in the EU, and that they will also look carefully at all possibilities to submit the drug to other international authorities. Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim …